Biocon Biologics secures multiple market access agreements in US for Yesintek
Business 05 May, 2025

Biocon Biologics secures multiple market access agreements in US for Yesintek

Business Aajkal, New Delhi, 05 May 2025: Biocon Ltd announced that its subsidiary, Biocon Biologics Ltd, has secured multiple market access agreements in the United States for its biosimilar drug Yesintek (ustekinumab-kfce), a version of Stelara, which is used to treat Crohn's disease, ulcerative colitis, plaque psoriasis, and psoriatic arthritis.
The company stated in a regulatory filing that these agreements collectively provide coverage across over 100 million lives in the U.S., marking a significant commercial breakthrough for Yesintek. The achievement positions Biocon Biologics as a key player in the competitive biosimilars market, particularly in the high-value immunology segment.

Related News